cgoncology.com (CGON) - Company Sales

CG Oncology - graphic logo of issuer CGON

Competition with pharmaceutical industry behemoths creates risks for CG Oncology, Inc. (CGON) trial timelines, which impacts the company's product rollout schedule, where the indicator stands at 0.01. The application of AI accelerates therapy discovery, although medical personnel remain indispensable. Aggressive specialist recruitment and generous employee bonuses support the commercial growth of urological drugs, strengthening the issuer's market position.

CGON CG Oncology Therapeutics Company Sales (02/21/2024 - 11/18/2026)

Analytical breakdowns for CG Oncology, Inc.

- market price and analyst price targets:
Summary company analysis:CGON cgoncology.com
Original product of CG Oncology Therapeutics

The operational efficiency of CG Oncology, Inc. (CGON) depends directly on the commercialization of drugs within a narrow oncological segment, where any research failures create critical risks. This metric aggregates daily cash inflows from transactions, allowing investors to promptly assess market demand through changes in the company's sales volume and adjust the asset's valuation in a timely manner.

Analysis of competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Sales Revenue URGN|bicara.com - Revenue and Sales Volume|Company Sales Revenue PSNL (personalis.com)|Erasca Inc (ERAS) - Company Revenue|Company Sales Delcath Systems|YMAB (YmAbs) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue